Factor VIII gene therapy - Cell Genesys
Latest Information Update: 24 Oct 2021
At a glance
- Originator Cell Genesys; Salk Institute
- Class Blood coagulation factors; Coagulants
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Haemophilia A
Most Recent Events
- 18 Jun 2003 Data presented at the 6th Annual Meeting of the American Society of Gene Therapy (ASGT-2003) have been added to the Gene Therapy and Haematological therapeutic trials section
- 04 Feb 2003 Discontinued - Preclinical for Haemophilia A in USA (unspecified route)
- 28 Jun 2002 A preclinical study has been added to the pharmacodynamic section ,